NCT06618196View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

April 30, 2026

Conditions
DiphtheriaTetanusPertussisHepatitis BPoliomyelitisHaemophilus Influenzae Type B Infection
Interventions
BIOLOGICAL

LR20062

DTaP-HepB-IPV-Hib vaccine

BIOLOGICAL

DTaP-HepB-IPV-Hib vaccine

Control hexavalent vaccine

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT06618196 - Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age | Biotech Hunter | Biotech Hunter